Biological activity of a combination of fulvestrant 500 mg (F500) plus anastrozole versus F500 alone or anastrozole alone as neoadjuvant treatment for breast cancer [Abstract]

Robertson, J. F. R., Dixon, J. M., Sibbering, D. M., Jahan, A., Ellis, I. O., Channon, E., Nicholson, Robert Ian and Gee, Julia Margaret Wendy ORCID: https://orcid.org/0000-0001-6483-2015 2010. Biological activity of a combination of fulvestrant 500 mg (F500) plus anastrozole versus F500 alone or anastrozole alone as neoadjuvant treatment for breast cancer [Abstract]. EJC Supplements 8 (3) , p. 63. 10.1016/S1359-6349(10)70050-1

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Additional Information:	Abstract Book EBCC7 - European Breast Cancer Conference
Publisher:	Elsevier
ISSN:	1359-6349
Last Modified:	18 Oct 2022 14:18
URI:	https://orca.cardiff.ac.uk/id/eprint/17110

Actions (repository staff only)

Edit Item